Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Epadel OTC to Be Reclassified as “Class 1” Category under Stricter Rules on Sales: MHLW Panel
A health ministry’s drug safety panel approved on April 2 the reclassification of a switch-OTC version of Mochida Pharmaceutical’s hyperlipidemia treatment Epadel (ethyl icosapentate), which is currently classified as a “behind-the-counter (BTC) drug”, as a Class 1 OTC drug under…
To read the full story
Related Article
- No More Nonprescription Switches for Lifestyle Disease Drugs, Says JMA Exec
April 5, 2019
- JMA Reps Oppose Reclassification of Epadel OTC despite No Serious ADR Reports: MHLW Safety Panel
March 26, 2019
- At Request of JMA, Pharmacists to Be Required to Confirm that Buyers of Switch OTC Version of Epadel Had Medical Exam Before Purchase
January 15, 2013
- PAC Approves OTC Switching of Epadel
December 21, 2012
- MHLW to Initially Limit Number of Stores to Offer Epadel OTC
October 26, 2012
- PAFSC Committee Recommends Approval for Switch OTC Version of Epadel 2 Years after Frist Review
October 18, 2012
REGULATORY
- Chuikyo Payers Signal Mixed Views on Off-Year Drug Price Revisions
February 16, 2026
- Chuikyo Issues FY2026 Fee Revision Recommendation, Creates New Premiums for Generics and Biosimilars
February 16, 2026
- Japan Panel to Review Sumitomo, Cuorips iPSC Products on Feb. 19
February 16, 2026
- Update: DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
- MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…